Thomas John Dietz is Director of Paratek Pharmaceuticals, Inc.. Currently has a direct ownership of 0 shares of PRTK, which is worth approximately $0. The most recent transaction as insider was on Sep 21, 2023, when has been sold 69,250 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
0% 3M change
0% 12M change
Total Value Held $0

Thomas John Dietz Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 21 2023
SELL
Sale (or disposition) back to the issuer
-
69,250 Reduced 100.0%
0 Common Stock
Feb 08 2023
BUY
Grant, award, or other acquisition
-
20,000 Added 22.22%
70,000 Common Stock
Feb 16 2022
BUY
Grant, award, or other acquisition
-
20,000 Added 28.57%
50,000 Common Stock
Feb 18 2021
BUY
Grant, award, or other acquisition
-
9,000 Added 23.08%
30,000 Common Stock

Also insider at

LPTX
LEAP THERAPEUTICS, INC. Healthcare
EIGR
Eiger BioPharmaceuticals, Inc. Healthcare
TJD

Thomas John Dietz

Director
Cambridge, MA

Track Institutional and Insider Activities on PRTK

Follow Paratek Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PRTK shares.

Notify only if

Insider Trading

Get notified when an Paratek Pharmaceuticals, Inc. insider buys or sells PRTK shares.

Notify only if

News

Receive news related to Paratek Pharmaceuticals, Inc.

Track Activities on PRTK